Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PureTech Health plc - American Depositary Shares (NQ:PRTC)

19.07 +0.07 (+0.36%)
Streaming Delayed Price Updated: 1:57 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PureTech Health plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
From PureTech Health plc
Via Business Wire
PureTech Announces Leadership Transition
From PureTech Health plc
Via Business Wire
PureTech Announces Board Change
From PureTech Health plc
Via Business Wire
Earnings Scheduled For April 30, 2025
 
Via Benzinga
Why This Biotech Stock Just Doubled In A Single Day
Vor Biopharma shares surge 43% after licensing deal, $175M raise, and CEO transition. 
Via Benzinga
PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
From PureTech Health plc
Via Business Wire
PureTech Health: Results of Annual General Meeting
From PureTech Health plc
Via Business Wire
PureTech to Present at the Jefferies Global Healthcare Conference
From PureTech Health plc
Via Business Wire
PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial
From PureTech
Via Business Wire
PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)
From PureTech Health plc
Via Business Wire
PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
From PureTech Health plc
Via Business Wire
PureTech Announces Annual Results for Year Ended December 31, 2024
From PureTech Health plc
Via Business Wire
PureTech Health: Notice of Results
From PureTech Health plc
Via Business Wire
PureTech Appoints Peel Hunt as Joint UK Corporate Broker
From PureTech Health plc
Via Business Wire
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
PureTech Health plc Statement Regarding Press Speculation
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
From PureTech Health plc
Via Business Wire
PureTech to Present at the Leerink Partners Global Healthcare Conference
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform
From PureTech Health plc
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
From PureTech Health plc
Via Business Wire
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
From PureTech Health plc
Via Business Wire
PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference
From PureTech Health plc
Via Business Wire
PureTech Appoints UBS as UK Corporate Broker
From PureTech Health plc
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
PureTech's Lung Disease Candidate Slowed Lung Function Decline In Idiopathic Pulmonary Fibrosis Patients
PureTech Health's Phase 2b trial of deupirfenidone for IPF met its primary endpoint, showing significant lung function improvement and dose-dependent benefits. 
Via Benzinga
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
From PureTech Health plc
Via Business Wire
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting
From PureTech Health plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback